Lineage Cell Therapeutics (LCTX) Minority Interest (2010 - 2026)

Lineage Cell Therapeutics has reported Minority Interest for 17 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Minority Interest rose 14.06% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$1.2 million (up 14.06% YoY), and the FY2025 full-year result was -$1.2 million, up 12.13% from the prior year.
• Minority Interest for Q1 2026 stood at -$1.2 million, up from -$1.2 million in the prior quarter.
• The five-year high for Minority Interest was -$1.2 million in Q1 2026, with the low at -$1.5 million in Q3 2023.
• Historically, Minority Interest has averaged -$1.4 million across 5 years, with a median of -$1.4 million in 2024.
• Annual changes were most pronounced in 2022 — Minority Interest declined 24.22% — and 2026, when it advanced 14.06%.
• Lineage Cell Therapeutics' Minority Interest stood at -$1.4 million in 2022, then increased by 0.5% to -$1.4 million in 2023, then grew by 1.93% to -$1.4 million in 2024, then climbed by 12.13% to -$1.2 million in 2025, then climbed by 1.91% to -$1.2 million in 2026.
• The last three Minority Interest figures came in at -$1.2 million (Q1 2026), -$1.2 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.